Clinical Trials

Medicenna recognizes that patient participation in clinical trials is critical in order to advance treatments for cancer and is developing its lead product MDNA55 in the clinic for cancers that have a significant unmet medical need. MDNA55 is currently being studied in a Phase 2b clinical trial for the treatment of recurrent glioblastoma. The trial is fully enrolled and not recruiting patients at this time.